LRMR - Larimar Therapeutics, Inc.
IEX Last Trade
4
0.050 1.250%
Share volume: 11,911
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$3.95
0.05
1.27%
Fundamental analysis
26%
Profitability
25%
Dept financing
6%
Liquidity
50%
Performance
25%
Performance
5 Days
-4.55%
1 Month
-38.83%
3 Months
-40.28%
6 Months
-46.15%
1 Year
-16.00%
2 Year
-13.30%
Key data
Stock price
$4.00
DAY RANGE
$3.70 - $4.04
52 WEEK RANGE
$3.99 - $13.68
52 WEEK CHANGE
-$17.83
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Carole S. Ben-Maimon
Region: US
Website: larimartx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: larimartx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.
Recent news